Key clinical point: Pharmacologic prophylaxis should not be used routinely for migraine in children.
Major finding: Weak evidence of efficacy was found only for propranolol (standardized mean difference, 0.60) and topiramate (SMD, 0.59).
Study details: Network meta-analysis of 23 studies, n = 2,217.
Disclosures: Dr. Zernikow has no relevant financial disclosures. One study author received grants from Amgen and other support from Grunenthal and Akelos. The study received funding from the Sara Page Mayo Endowment for Pediatric Pain Research, Education, and Treatment; the Swiss National Science Foundation; the Schweizer-Arau-Foundation; and the Theophrastus Foundation.